glp-1 drugs review The New GLP-1 Genetics: How Genes Affect

doi: 10.3389/fendo.2019.00389 Received 07 April 2019 Accepted 30 May 2019 Published 19 June 2019 Volume 10 - 2019 Edited by Jens Juul Holst, University of Copenhagen, Denmark Reviewed by Leon Bach, Monash University, Australia

The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose levels are elevated Suppressing glucagon release from pancreatic alpha cells, which reduces hepatic glucose production Slowing gastric emptying , which helps moderate post-meal blood glucose spikes Reducing appetite through central nervous system effects, leading to decreased caloric intake and weight loss Examples of GLP-1 receptor agonists available in the UK include exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for weight management), dulaglutide (Trulicity), lixisenatide (Lyxumia), and semaglutide (Ozempic/Rybelsus for diabetes, Wegovy for weight management)

consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk

Glucagon-like peptide-1 receptor agonists during pregnancy and lactation

Data availability statement No additional data available

In alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, Placebo-Controlled, double-blind clinical trial